Expression of Ki67 and PTEN in benign endometrial hyperplasia and Endometrial Intraepithelial Neoplasia
Abstract
Uterine carcinoma is the most common neoplastic disease in the female genital tract and progress from a common precursor lesion, atypical hyperplasia. The current study used immunohistochemistry to detect the Ki67 and PTEN expression in 49 endometrial cases distributed as normal, disordered proliferative endometrium, benign endometrial hyperplasia and endometrial Intraepithelial Neoplasia EIN samples. IHC statistical analysis recorded significant differences P≤0.01 all samples in EIN sample especially between normal and atypical hyperplastic lesions. Complete loss of PTEN expression was 66.6% in atypical hyperplastic lesion samples then 13.3% in non- atypical hyperplastic cases. PTEN intensity in non- atypical hyperplastic cases was significant p= 0.0392 compared with
normal and atypical hyperplastic tissue which was highly significant intensity P 0.0059, P 0.0023 respectively. In Ki67, all endometrial cases were highly significant P≤0.01. All atypical EH (EIN) showed positive Ki67 expression with high significant p value (0.0074) and 66.6% of cases was in score 3 compared with 3.3% of benign EH. The high percentage of both Ki67 scoring and intensity with null PTEN expression compared with the other hyperplastic lesion confirm the probability of these cases as a precancer lesion, precursor for uterine carcimoma.
Downloads
References
Lakhani A, Wani RV, Pilli GS. Expression of PTEN Marker in Endometrial Hyperplasia without Atypia: One-year Observational Study. J South Asian Feder Obst Gynae (2023); 15(1): 1–4.
Vereshchahina TV, Boychuk AV, Yakymchuk YB, Nikitina IM, Datsko TV. Morphological changes of the endometrium in hyperplastic process in women of reproductive age. Wiad Lek. (2021); 74(3 cz 1):388-394. PMID: 33813438.
Travaglino A, Raffone A, Saccone G, Mollo A, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology, (2019) Apr;74(5):676-687.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
